PIPELINE.

Our pipeline strategy is simple.

Overall, our plan is to be a supplier of needed therapeutics to commercialization entities. This path allows us to produce meaningful revenue and mitigate risk.

We will focus in four areas:

Biosimilars
Novel Drugs
Animal Health
Clinical Trial Investigation

Because we are non-binary, and are not tied to a single product/candidate, Phylloceuticals can pivot to meet market demand.

Producing biosimilars at one-tenth the cost per gram is disruptive. The main driver for biosimilars is to provide products that are essentially "similar" to needed biologics in safety and efficacy. Phylloceuticals biosimilar products can be made to client specifications and are ready to screen on an expedited timeline. In addition, clean-profile biosimilars made in plant cells offer our partners a differentiating advantage, as the demand for details on food and medicine sourcing continues to grow.

Phylloceuticals has already shown its capacity to make blockbuster biosimilars, (we'll show you the data) including PD-1 inhibitors.

Biosimilars

Today, Data Scientists sit alongside classically trained R&D bench scientists. AI is being used to screen millions of potential solutions, previously unimagined, for target molecules. Some molecules have always been too challenging for mammalian cell culture or current manufacturing platforms to handle.

Phylloceuticals' plant-based platform has distinct advantages in handling folding, sugar optimization and other challenges at the drug development stage. Our "speed-to-screen" ability with rapid growth and high biomass production can screen the massively higher number of candidates being produced by AI, in a cost effective manner. Bispecifics, for example, where bsABs are engineered to bind to two distinct targets, is a sweet spot for us. One could say that Phylloceuticals enables the potential of AI to become real for novel therapeutics and beyond.

Novel Therapeutics

Phylloceuticals has found a warm welcome inside the animal health industry. Interest in producing medicine without growth hormones or other contaminants for animals continues. As a trusted supplier for this industry, who increasingly prefer plant-based products for livestock and pets, we see a strong alignment with the Phylloceuticals mission and vision.

Animal Health

Scientists begin with an idea. The next step is a need to screen promising candidates, quickly, to narrow down the field. Producing human therapeutic proteins for screening can be accomplished in weeks, not months, with Phylloceuticals' plant-based platform.

How? The plant we use is one of the fastest growing plants on the planet.

And for clinical trial investigators, testing early stage ideas should not cost a blockbuster price. (We can help with that, too.)

Clinical Trial Investigation

WHAT’S NEXT STARTS HERE.

Get in touch at info@phylloceuticals.com